Understanding Bile Duct Cancer Pathology, IHC and Genomic Reports

Pathology, immunohistochemistry (IHC) and genomic reports help explain what type of cancer is present, where it may have come from, and whether important markers or mutations could affect treatment options.

Why These Reports Matter

After a bile duct cancer or biliary tract cancer diagnosis, patients are often given complex reports filled with unfamiliar words.

These reports can feel technical, but they are not just paperwork.

They help answer three important questions:

  • What type of cancer is this?
  • Where does the cancer appear to have come from?
  • Are there markers or mutations that could affect treatment options?

Understanding these reports helps patients ask better questions, avoid missed opportunities and keep more options open.

What Is Pathology?

Pathology is the examination of cells and tissue to understand disease.

When a biopsy is taken, a pathologist studies the sample under a microscope.

They look at the shape of the cells, how the cells are arranged, whether they look abnormal, and whether the pattern fits with cancer.

In bile duct cancer, pathology helps confirm whether the tumour is an adenocarcinoma, meaning a gland-forming epithelial cancer.

Epithelial cells are lining cells. They line ducts, glands, tubes and organ surfaces.

Cholangiocytes are the specialised epithelial cells that line the bile ducts.

What Is Immunohistochemistry?

Immunohistochemistry is often shortened to IHC.

IHC uses special stains to look for proteins inside or on the surface of cells.

These proteins are called markers.

Markers can help pathologists understand what type of cell is present and where a cancer may have started.

Think of IHC like checking the labels inside a machine.

The machine may be damaged, but the labels can still give clues about what kind of machine it is and where it came from.

Common IHC Markers In Bile Duct Cancer

CK7 and CK19 are commonly seen in bile duct and other ductal epithelial cells.

They help support bile duct or pancreaticobiliary origin, but they do not prove bile duct cancer by themselves.

Other markers may also be used depending on the case.

  • CK7: commonly supports bile duct, pancreaticobiliary and other glandular epithelial patterns.
  • CK19: commonly supports ductal epithelial origin, including bile duct-type cells.
  • CK20: may suggest intestinal or gastrointestinal patterns, depending on the wider marker profile.
  • CDX2: may support intestinal-type differentiation when present.
  • SATB2: can help support colorectal origin when positive in the right pattern.
  • TTF-1: may help assess lung or thyroid origin.
  • PAX8: may help assess kidney, thyroid or gynaecological origin.
  • MMR markers: help assess mismatch repair status, which may affect immunotherapy options.

No single marker gives the full answer.

The pattern matters.

The pathologist interprets IHC alongside cell appearance, tumour location, imaging, clinical history and other test results.

What Is A Genomic Report?

A genomic report looks for changes in cancer DNA.

These changes are often called mutations, alterations or variants.

In bile duct cancer, genomic testing can be important because some mutations may create treatment or clinical trial opportunities.

Genomic testing does not replace pathology.

It adds another layer of information.

Pathology helps explain what the cancer looks like.

IHC helps explain what markers the cancer expresses.

Genomics helps explain what may be driving the cancer at the DNA level.

Important Genomic Markers In Cholangiocarcinoma

Some genomic alterations are especially important in cholangiocarcinoma and biliary tract cancers.

  • FGFR2: more commonly seen in some intrahepatic cholangiocarcinomas and may be targetable.
  • IDH1: may be targetable in selected cases.
  • BRAF: may create targeted therapy options in some cancers.
  • HER2 or ERBB2: may be relevant in some biliary tract cancers, especially gallbladder cancer and extrahepatic cholangiocarcinoma, and may create targeted therapy options in selected cases.
  • NTRK: rare, but important because it may be highly targetable.
  • BRCA1 and BRCA2: may affect DNA repair and treatment options in selected cases.
  • KRAS: can be an important driver mutation and may influence treatment strategy.
  • MSI-H or dMMR: may indicate potential benefit from immunotherapy.
  • PD-L1: may help assess whether the cancer is using an immune “brake” signal, and may support immunotherapy decision-making in some settings.
  • TMB: tumour mutational burden may help assess immunotherapy relevance in some settings.

Not every patient will have a targetable mutation.

But every eligible patient should ask whether genomic profiling has been done, whether the sample was sufficient, and whether a clinical trial may be relevant.

How These Reports Work Together

Pathology, IHC and genomic reports should not be read as separate islands.

They work together.

Think of the cancer like a failed engine.

Pathology shows what the damaged engine looks like.

IHC shows some of the labels and parts inside the engine.

Genomics looks for damaged instructions in the engine’s control system.

When these layers are combined, the picture becomes clearer.

Questions Patients Can Ask

  • What exact type of cancer does the pathology report describe?
  • Does the marker pattern support bile duct, pancreaticobiliary or another origin?
  • Which IHC markers were tested?
  • Was MMR testing performed?
  • Was MSI tested by IHC, PCR or genomic testing?
  • Was full genomic profiling performed?
  • Was the tissue sample large enough for genomic testing?
  • If tissue was insufficient, should a liquid biopsy be considered?
  • Were FGFR2, IDH1, BRAF, HER2, NTRK, BRCA, KRAS, MSI and TMB assessed?
  • Could any result affect treatment, clinical trials or second opinion review?

Why This Matters For Keeping Options Open

In cholangiocarcinoma, timing matters.

Some treatment opportunities are missed because testing happens too late, tissue runs out, or results are not reviewed early enough.

Understanding pathology, IHC and genomic reports helps patients and caregivers recognise what information is still missing.

That can help guide second opinions, molecular testing, trial matching and treatment planning.

For treatment decision-making, read Keep Options Open.

Related Articles

Trusted Information

Further trusted information is available from the National Cancer Institute bile duct cancer information, the American Cancer Society bile duct cancer guide, and the ESMO biliary cancer guideline.

Final Plain-Language Summary

Pathology tells us what the cancer looks like.

IHC markers help show what type of cell the cancer resembles and where it may have come from.

Genomic testing looks for DNA changes that may affect treatment options or clinical trial opportunities.

For bile duct cancer and biliary tract cancers, these reports are not just technical documents.

They are survival information.

They help patients understand what is known, what is missing, and what should be asked next.